JS
Jwalant Sureshbhai Shah
About Jwalant Sureshbhai Shah
Data last updated:
Jwalant Sureshbhai Shah has 17 years in corporate governance. Holds Director and Whole-Time Director roles. Currently with 23 companies, including Advanced Transfusion Medicine Research Foundation and Unipath Specialty Laboratory Limited. Formerly with 3 companies, such as Unidrg Specialty Laboratory Llp and Octa Specialty Laboratory Llp. Engaged in General Business, Healthcare. The 5 current companies with reported revenue have a combined latest revenue of ₹265 Cr; the largest is Unipath Specialty Laboratory Limited at ₹183 Cr (FY 2024).
Current companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
 Unipath Specialty Laboratory Limited U85195GJ2009PLC057059 | Whole-Time Director | 26 May 2009 | 2009 | ₹183 Cr (FY 2024) | Active |
 Ravula Unipath Health Care Private Limited U86905TS2023PTC172315 | Director | 27 May 2025 | 2023 | ₹55.55 Cr (FY 2025) | Active |
| Simira Unipath Diagnostics Private Limited U85190MH2020PTC335458 | Director | 06 Jan 2024 | 2020 | ₹14.78 Cr (FY 2024) | Active |
 Advanced Transfusion Medicine Research Foundation U19129GJ1997NPL032264 | Director | 27 Feb 2012 | 1997 | ₹7.50 Cr (FY 2022) | Active |
| Designated Partner | 06 Nov 2019 | 2019 | ₹3.30 Cr (FY 2023) | Active | |
| Unipath Specialty Laboratory (Baroda) Private Limited U86905GJ2025PTC170911 | Director | 19 Dec 2025 | 2025 | – | Active |
| Dr. Sanjay Mehta Unipath Speciality Laboratory Private Limited U86905MH2024PTC435523 | Director | 27 Nov 2024 | 2024 | – | Active |
| Bioscape Healthspan Private Limited U86905GJ2024PTC154541 | Director | 20 Aug 2024 | 2024 | – | Active |
Previous companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
| Unidrg Specialty Laboratory Llp AAZ-4713 | Designated Partner | 15 Nov 2021 | 2021 | – | Active |
| Octa Specialty Laboratory Llp AAV-9429 | Designated Partner | 17 Feb 2021 | 2021 | – | Active |
| Designated Partner | 01 Aug 2025 | 2019 | ₹24.27 Cr (FY 2023) | Converted And Dissolved |
Explore Director's current and past company associations Uncover their professional journey today!
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Jwalant Sureshbhai Shah
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Jwalant Sureshbhai Shah
Jwalant Sureshbhai Shah has 17 years in corporate governance. Holds Director and Whole-Time Director roles. Currently with 23 companies, including Advanced Transfusion Medicine Research Foundation and Unipath Specialty Laboratory Limited. Formerly with 3 companies, such as Unidrg Specialty Laboratory Llp and Octa Specialty Laboratory Llp. Engaged in General Business, Healthcare. The 5 current companies with reported revenue have a combined latest revenue of ₹265 Cr; the largest is Unipath Specialty Laboratory Limited at ₹183 Cr (FY 2024).
Jwalant Sureshbhai Shah is associated with 23 companies as Director and Whole-Time Director, including Unipath Specialty Laboratory Limited (₹183 Cr), Ravula Unipath Health Care Private Limited (₹55.55 Cr), Simira Unipath Diagnostics Private Limited (₹14.78 Cr).
Jwalant Sureshbhai Shah has expertise in General Business, Healthcare.
Jwalant Sureshbhai Shah has 17 years in corporate governance.
By reported revenue, the largest current company of Jwalant Sureshbhai Shah is Unipath Specialty Laboratory Limited, with revenue of ₹183 Cr (FY 2024).
The 5 current companies of Jwalant Sureshbhai Shah that report revenue have a combined latest revenue of ₹265 Cr.
Jwalant Sureshbhai Shah currently holds positions at 23 companies; the 5 largest by reported revenue are Unipath Specialty Laboratory Limited (₹183 Cr), Ravula Unipath Health Care Private Limited (₹55.55 Cr), Simira Unipath Diagnostics Private Limited (₹14.78 Cr), Advanced Transfusion Medicine Research Foundation (₹7.50 Cr), Kansagara Unipath Specialty Laboratory Llp (₹3.30 Cr).